Surgery Websites
Hepatobiliary & Pancreatic Surgery »  Meet the Team »  Hepatology »  Francis Y.K. Yao, M.D.
Francis Y.K. Yao, M.D.

Francis Y.K. Yao, M.D.

  • Professor of Clinical Medicine and Surgery,
  • Departments of Medicine and Surgery
  • Medical Director, Liver Transplant Service
  • Director for Community Liaison, Liver Transplant Service

Contact Information

Academic Office
Division of Gastroenterology
513 Parnassus Avenue, Room S-357
San Francisco, CA 94143-0358
Phone: (415) 514-0332
Fax: 415-476-0659
Open Popup

1979-1980 University of San Francisco, Chemistry Major

1980-1983 University of California, Berkeley B.S. Chemistry with High Honors

1983-1987 Albert Einstein College of Medicine. M.D. Medicine

  • 1987-1988 Stanford University Hospital, Intern, Internal Medicine
  • 1988-1990 Stanford University Hospital, Resident, Internal Medicine
  • 1990-1993 Stanford University Hospital, Fellow, Gastroenterology
  • 1995 American Board of Internal Medicine - ABIM 147033 (Re-certification 2008)
  • 1997 American Board of Gastroenterology - ABIM 147033
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Liver Transplant Program
  • UCSF Liver Center
  • Hepatitis in Asians
  • Liver Injury and Repair
  • Liver transplantation outcomes including expanded criteria liver transplants
  • Loco-regional therapy for hepatocellular carcinoma

Dr. Francis Yao is a gastroenterologist and medical director of the Liver Transplant Program at UCSF Medical Center. Dr. Yao is a professor of medicine in the UCSF School of Medicine. He also is director of UCSF's Liver Transplant Outreach and Community Liaison Program. In his research, he is interested in liver cancer treatment, particularly related to liver transplants, and has contributed to important publications in this area. His other research interests include hepatitis B infection and outcomes for liver transplantation.

Data provided by UCSF Profiles, powered by CTSI
  1. Huang AC, Dodge JL, Yao FY, Mehta N. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers. Clin Gastroenterol Hepatol. 2022 Aug 28. View in PubMed
  2. Giard JM, Dodge JL, Yao FY, Mehta N. Alpha-fetoprotein slope over 7.5 ng/ml over 3 months before liver transplantation for hepatocellular carcinoma predicts recurrence even after controlling for alpha-fetoprotein at liver transplantation. Liver Transpl. 2023 Feb 01; 29(2):233-235. View in PubMed
  3. Silverstein J, Yao FY, Grab JD, Braun HJ, Roberts J, Dodge JL, Mehta N. National experience with living donor liver transplantation for hepatocellular carcinoma. Liver Transpl. 2022 07; 28(7):1144-1157. View in PubMed
  4. Goldman ML, Zhou K, Dodge JL, Yao F, Mehta N. Lower Alpha-Fetoprotein Threshold of 500 ng/mL for Liver Transplantation May Improve Posttransplant Outcomes in Patients With Hepatocellular Carcinoma. Liver Transpl. 2022 05; 28(5):763-773. View in PubMed
  5. Bernards S, Hirose R, Yao FY, Jin C, Dodge JL, Huang CY, Mehta N. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma. Liver Transpl. 2022 03; 28(3):376-385. View in PubMed
  6. View All Publications


Site Directory